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Abstract: Western Pacific amyotrophic lateral sclerosis and parkinsonism-dementia 
complex, a disappearing neurodegenerative disease linked to use of the neurotoxic cycad 
plant for food and/or medicine, is intensively studied because the neuropathology 
(tauopathy) is similar to that of Alzheimer’s disease. Cycads contain neurotoxic and 
genotoxic principles, notably cycasin and methylazoxymethanol,  the latter sharing 
chemical relations with nitrosamines, which are derived from nitrates and nitrites in 
preserved meats and fertilizers, and also used in the rubber and leather industries. This 
review includes new data that influence understanding of the neurobiological actions of 
cycad and related genotoxins and the putative mechanisms by which they might trigger 
neurodegenerative disease. 
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1. Introduction 
Neurobiology provides a solid foundation on which to explain the molecular pathogenesis of most 
chemically triggered brain diseases, including self-limiting human neurodegenerative disorders. For 
example, substances with neurotoxic potential may bind to membrane receptors, enter cells via 
membrane channels, interfere with mitochondrial function, disrupt axonal transport, or perturb 
synaptic integrity. The resulting neurocellular dysfunction presages functional changes that may 
remain sub-clinical or find clinical expression in minutes, hours, days or weeks. The associated clinical 
disorder peaks over time, plateaus and either persists or resolves. Thus, chemical exposure produces a 
self-limiting neurological disorder by activating an abnormal physiologic state that reverses or, with 
cell loss, persists, but does not advance. True, the neurological condition may relapse or progress in 
the event of continued chemical exposure or the release of an endogenously stored substance, but 
chemicals that act through the foregoing cellular mechanisms are considered unable to trigger a   
self-propelling disorder that results in the relentless, unstoppable advance of neurological disease. If 
chemicals are ever found to induce progressive and ultimately fatal neurodegenerative diseases, a 
fundamentally different neurotoxic molecular mechanism must be involved [1,2]. 
Ten years ago, we embarked on a voyage to discover that mechanism because of the existence of an 
intensively studied progressive  neurodegenerative disorder that unequivocally seems to have an 
environmental origin and a non-infectious etiology. This fatal disease is a complex clinical mixture of 
amyotrophic lateral sclerosis (ALS), parkinsonism (P) and dementia (D) with a neuropathology 
comparable to that of Alzheimer disease (AD) [3]. The affected brain accumulates many types of 
abnormal intracellular deposits (synuclein, -amyloid, TDP-43), but it is dominated by deposits of 
microtubule-associated protein tau (MAPT), and therefore fits into the molecular neuropathological 
class of tauopathies [4]. The clinical and neuropathological features of this disease are best studied 
among Chamorro residents of the Mariana Islands of Guam and Rota [5] and among Japanese living  
in the Kii Peninsula of Honshu Island, Japan [6,7]. Least studied and without neuropathologic 
conformation is a third isolate of western Pacific ALS-PD complex (ALS-PDC) among Auyu and 
Jaqai linguistic groups in the southern lowlands of West Papua, on the Indonesian side of the island of 
New Guinea [8,9]. These three genetically distinct groups of people have experienced an 
extraordinarily high prevalence of this prototypical neurodegenerative disease, the latter flourishing in 
a setting in which no synthetic chemicals had ever ‘set foot’ at the time of its discovery. The same 
disease is non-transmissible from human to monkey, in contrast to kuru, a distinct but also 
disappearing neurodegenerative disorder formerly found among the South Fore people in the highlands 
of Papua New Guinea that is believed to have an infective prion etiology [10,11].  
The foregoing information suggests the operation of a naturally occurring environmental substance 
in the etiology of Western Pacific ALS-PDC. The only factor common to all three ALS-PDC foci is 
use for food and/or medicine of the seed of the hardy cycad plant (Cycas spp., Figures 1 and 2). Like 
all plant materials, the cycad seed is a complex mixture of chemicals, one of which (cycasin) is the 
principal subject of this paper. We hypothesize that the aglycone of cycasin, the potent genotoxin 
methylazoxymethanol (MAM), persistently perturbs cell signaling in the young adult brain because 
post-mitotic nerve cells are unable to repair MAM-induced DNA damage. We have solid evidence to 
support this conclusion for the developing rodent brain, which MAM readily disrupts, and the Int. J. Environ. Res. Public Health 2011, 8         
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fingerprints of a comparable mode of action in the central nervous system of the young adult. If we are 
correct, MAM represents the first recognized agent with neurotoxic properties that produces a long-
latency progressive neurodegenerative disease, where the interval between agent exposure and onset of 
neurological decline spans years or decades. We also present evidence that MAM perturbs   
cell-signaling pathways in the brain that are similar to those activated in mitotically-competent 
(cycling) epithelial cells that mutate and proliferate to form malignant tumors. This leads us to propose 
the possibility that cellular malignancy and progressive neurodegeneration are two sides of the same 
coin, the outcome depending on whether the genotoxin acts on a cycling or non-cycling cell, 
respectively. Since this idea deviates markedly from current understanding and has significant 
consequences for disease prevention and treatment, we hope our work will stimulate research on this 
question to prove or disprove our assertion. 
Figure 1. Cycad distribution in the western Pacific region (A) and photograph of a Cycas 
circinalis plant (B). 
(A)                    (B) 
             
We embark on this review cognizant of the incompleteness of the data we review in support of our 
hypothesis that unrepaired MAM-induced neuronal DNA damage perturbs cellular networks that may 
initiate neurodevelopmental delay in the immature brain or progressive neurodegeneration that begins 
in the young adult brain and appears clinically years or decades later in the form of the tauopathy  
ALS-PDC. Further, given the close neuropathological relationship between ALS-PDC and AD, we 
explore how new understanding of the former influences thinking about the possible role of 
environmental agents in the etiology of AD. Int. J. Environ. Res. Public Health 2011, 8         
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Figure 2. Cut seed of Cycas micronesia, a plant indigenous to Guam and the Micronesian 
islands, are processed for food by washing the halved or quartered seeds in water and 
laying them out to dry (A). Pharmacist in ALS-PDC focus in Kii Peninsula, Japan holding 
a labeled bottle of Cycas revoluta seed (sotetsu) and a textbook of folk medicine describing 
pharmaceutical indications for their medicinal usage (B). 
(A)                                                                               (B) 
                                  
 
2. Evidence for the Role of Cycads in ALS-PDC 
Since the etiology of western Pacific ALS-PDC is the subject of controversy, we should justify our 
position regarding the etiopathogenesis of this and other neurological diseases with which it has been 
compared. Several theories have been offered over the past 60+ years since high-incidence 
motorsystem disease was first recognized on Guam. Given its familial nature, inherited risk factors 
were first proposed, but with temporal decline in prevalence, some combination of genetic risk and 
environmental exposure was entertained. As disease rates continued to drop [12], the dominant clinical 
presentation changed over time from ALS to parkinsonism-dementia (PD) to Guam dementia (GD), 
and the age of onset continued to increase, it became increasingly clear that disease decline was most 
probably associated with a disappearing environmental exposure associated with the acculturation of 
Guam Chamorros to a western lifestyle. Screens of the Guam genome have failed to identify mutations 
responsible for Chamorro ALS-PDC but, in some cases, revealed polymorphisms in two independent 
cis-acting sites in the tau gene that might influence disease risk by regulating its   
expression [13]. Analysis of blood from Kii ALS-PDC subjects showed no mutations of 19 
neurodegenerative disease-relevant genes [14]. Another finding in a subset of Guam ALS and PDC 
patients was a variant in the gene coding for the transient receptor potential cation channel, subfamily 
M, member 7 (TPRM7) [15], which produced functional channels with an increased sensitivity to 
inhibition by intracellular Mg
2+ [16]. However, TPRM7 mutations have not been found in ALS-PDC 
cases in Kii peninsula [17]. ALS has also declined in the high-incidence disease focus of   
ALS-PDC in West Papua [9]. In sum, an inherited disorder is incompatible with the declining Int. J. Environ. Res. Public Health 2011, 8         
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prevalence of ALS-PDC in all three geographic isolates, and no common causal genetic factor has 
been identified. 
The longitudinal trend of ALS and PD, which has been documented epidemiologically for more 
than half a century on Guam, is consistent with an environmental agent that is declining hand-in-hand 
with post-World War II development of the island. Two hypotheses have been offered: one relates to 
declining use of the cycad plant for food and/or medicine [18], the other proposes that neurotoxic 
elements (such as aluminum and manganese) in water enter the body and are deposited in the brain. 
Low levels of calcium in water, it was suggested, triggered a parathyroid response that promoted gut 
absorption of calcium, with the result that absorption of “neurotoxic bystanders”, such as aluminum, 
would also take place [19]. While aluminum and other metals can be detected in the brain of Guam 
ALS-PDC patients, parathyroid function is unremarkable [20]. Additionally, in West Papua, ALS 
prevalence in a sessile, riverine population has declined without any known change in their source of 
drinking water [9]. 
The second environmental hypothesis focuses on exposures to neurotoxic components in seed of the 
cycad plant. The proposal originates from 1962 when the late Marjorie Whiting described the 
Chamorro practice of using cycad seeds for food and topical medicine [21]. Her research demonstrated 
that cycad plants had a long history in Australia and elsewhere of causing a neuromuscular disease in 
grazing animals. Cycads were found to harbor the first known plant mutagen, cycasin, and an 
uncommon amino acid, -N-methylamino-L-alanine (L-BMAA), which induced an acute neurotoxic 
syndrome in chicks [22]. Interest in the cycad hypothesis lapsed until, decades after Whiting’s 
pioneering observations, we showed that primates treated orally with L-BMAA developed chronic 
degenerative changes in cortical and spinal motor neurons in association with a clinical picture 
reminiscent of the western Pacific disease [23]. However, because of the very high L-BMAA dosage 
used in this typical short-term toxicology experiment, and lack of disease progression after dosing 
ceased, the relevance of this model to ALS-PDC was subject to question. The cycad hypothesis again 
fell into disfavor until it was suggested the dosage of L-BMAA used in the earlier primate studies was 
realistic given that the Chamorro diet included flying foxes that harbored large concentrations of   
L-BMAA [24]. It should be noted, however, that flying foxes are not part of the diet of Japanese or 
New Guinean subjects at risk for ALS-PDC. 
While Whiting emphasized the dietary use of cycads on Guam, the common exposure to cycad 
toxins in all three high-incidence disease foci is from raw cycad seed used for medicine, with the 
additional use on Guam of the fresh seed cover to relieve thirst, the dried seed cover as a confection, 
and washed but incompletely detoxified cycad ovules as a source of flour for various food products 
[21] (Figure 2A). The neurotoxic cycad seed has been used as a topical treatment for skin lesions large 
and small [25], but such use undoubtedly declined as man-made pharmaceuticals were introduced. 
Oral medicinal use of cycad seed was also practiced in Japanese folk medicine in the Kii focus up 
through the 1980s, with prescriptions written by practitioners (kitoshi) that were filled by dispensing 
pharmacies (Figure 2B) [26]. Repeated oral or prolonged subcutaneous application of raw cycad seed 
was thus common to all three ALS-PDC isolates. The Chamorros of Guam and Rota also used the 
cycad seed ovule as a source of food. This was not remarkable since aboriginal groups in Australia 
historically prepared food from carefully detoxified cycad seed ovules without precipitating recognized 
neurological disease. Similarly, Japanese living in the Ryukyu Islands, where ALS-PDC is unknown, Int. J. Environ. Res. Public Health 2011, 8         
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employed fermentation to eliminate cycasin [27]. Guam Chamorros, by contrast, used food preparation 
methods that only reduced the content of cycad toxins to “edible” levels that, while not lethal, 
nevertheless precipitated acute illness in children likely arising from the hepatotoxic properties of 
cycasin. We demonstrated residual levels of L-BMAA and cycasin in cycad flour prepared by families 
from different Guam villages [28]. 
2.1. Cycad Toxins: -N-Methylamino-L-Alanine (L-BMAA) 
L-BMAA is an uncommon amino acid that is synthesized by cyanobacteria and present in seed of 
Cycas spp. implicated in western Pacific ALS-PDC. Whether the amino acid is an endogenous cycad 
product or derived from invasive cyanobacteria is questioned. It should be noted that cyanobacteria 
also contain genotoxins that are capable of inducing DNA damage in both human and rodent   
cells [29]. We showed and others confirmed that L-BMAA is an excitotoxic amino acid with acute 
neurotoxic properties that are attenuated by glutamate receptor antagonists. Our group and several 
others have shown that L-BMAA has effects on both ionotropic and metabotropic glutamate   
receptors [30-33].  
Figure 3. Structures of the amino acid neurotransmitter L-glutamate and the excitotoxic 
amino acids -N-methylamino-L-alanine (L-BMAA) and N-oxalylamino-L-alanine  
(L-BOAA). Note the structural similarity between glutamate and both L-BMAA and   
L-BOAA. 
 
L-BOAA is a potent stereospecific amino acid in the Grass pea that acts in micromolar 
concentrations as an agonist of the -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) 
class of glutamate receptors. Although small concentrations of L-BOAA are present in cycad seed, 
lathyrism is a self-limiting pyramidal-tract disorder quite distinct from both the clinical form and 
progressive nature of western Pacific ALS-PDC. In a similar vein, domoic acid, which acts Int. J. Environ. Res. Public Health 2011, 8         
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predominantly as a AMPA/kainate glutamate receptor agonist [36], induces a rapid-onset self-limiting 
neurodegenerative disorder [37]. Based on these observations, it is unlikely that the chronic 
motorsystem disease induced in primates fed L-BMAA arises from a membrane-based glutamate 
receptor action of the cycad amino acid. Stated otherwise, if L-BMAA does have a role in the etiology 
of western Pacific ALS-PDC, a mechanism other than glutamate excitotoxicity must be responsible. 
One possibility is described in the following paragraph. 
L-BMAA might exert a chronic neurotoxic effect by being incorporated into protein, the foreign 
amino acid residue causing protein malfunction. The basis for this hypothesis comes from 
experimental evidence of significant levels of protein-associated L-BMAA in washed cycad flour and 
the detection of L-BMAA in the brain tissue of Guam Chamorros with ALS-PDC [38,39]. In support 
of this hypothesis, we showed that L-BMAA, but not L-BOAA, is taken up by cortical explants and 
synaptosomes in a time-dependent manner [40]. Previously unpublished data confirmed tissue uptake 
of L-BMAA in cortical explants treated with [
14C]-L-BMAA and in mouse cortical synaptosomes 
treated with [
3H]-L-BMAA (Figure 4). Additional data (not shown) demonstrated that L-BMAA is taken 
up and released from cortical synaptosomes. The rapid uptake, accumulation and release of L-BMAA, 
but not the structural analog L-BOAA, in cortical explants and synaptosomes suggest that the   
sub-chronic neurotoxic effects of this excitotoxin in primates is related to unknown intracellular actions. 
Figure 4. L-BMAA uptake into rat cortical explants, primary cortical astrocyte cultures 
and cortical synaptosomes after treatment with either L-[
14C]-BMAA or L-[
3H]-BMAA.  
(A) Uptake of L-
14C-BMAA in mature mouse cortical explants and primary rat cortical 
astrocytes 
1; (B) Distribution of L-[
14C]-BMAA in mature mouse cortical explants treated 
with 1.6 mM of the neurotoxin 
2; (C) L-[
3H]-BMAA uptake into mouse cortical 
synaptosomes as a function of isotope concentration 
3; (D) Effect of BMAA on   
L-[
3H]-BMAA uptake into mouse cortical synaptosomes 
4. Graphs derived from   
Kisby et al. [40] and unpublished data.  
 Int. J. Environ. Res. Public Health 2011, 8         
 
 
3896
Figure 4. Cont.  
 
1 Explants from the motor cortex of 2-day old Swiss Albino mice were maintained for 2–3 weeks   
in vitro whereas cortical astrocytes derived from 1–3 day-old neonatal Sprague-Dawley rats were maintained 
for 3–4 weeks before treatment with 1.6 mM L-[
14C]-BMAA (11.7 nCi/explant or culture) as previously 
described [40]. Note that the uptake of radiolabeled L-BMAA in mouse cortical explants was ~5-fold greater 
at 60 min than in comparatively treated rat cortical astrocytes. Values are mean ± standard error (n = 8–11 for 
explants and n = 6–7 for astrocytes) and corrected for non-specific binding of radiolabeled L-BMAA;   
2 Explants were treated for various time periods (up to 2 h) with the radiolabeled   
neurotoxin (11.7 nCi/explant), washed with PBS (pH 7.4) and then homogenized in PBS. The tissue 
homogenate was ultrafiltered (10 K MWCO), washed with PBS and the radioactivity determined in the 
retentate (bound) and filtrate (unbound or ‘free’). Values are mean ± standard error (n = 4). Note that the 
radioactivity was found primarily in the filtrate; 
3 Aliquots of L-[
3H]-BMAA (17.88 Ci/mL buffer) were 
diluted with buffer and incubated for 5 min with crude synaptosomes as previously described [40]. Values are 
mean ± standard error. Number of determinations per concentration is shown in parentheses. 
4 Synaptosomes 
were incubated for 5 min with radiolabeled neurotoxin (179 nCi) in the absence or presence of ‘cold’ BMAA 
(1.0 M–1000 M). Values are mean ± standard error. Number of determinations is shown in parentheses. 
Significantly different from treated synaptosomes incubated with L-[
3H]-BMAA (* p < 0.05, ** p < 0.01). 
Such a mechanism would be consistent with the slow evolution of motor neuron changes 
(chromatolysis) and the absence of excitotoxic damage in the frontal cortex of heavily dosed macaques 
exhibiting motorsystem (rather than convulsive) signs and the low levels of L-BMAA in the serum 
(micromolar) and cerebrospinal fluid (nanomolar) of one such animal [2,41]. Whether L-BMAA or its 
metabolite(s) target intracellular macromolecules critical for long-term maintenance of neuronal 
integrity is unknown. 
L-BMAA is also metabolized to toxic species in rat tissue slices, mouse cortical explants, and rat 
crude cerebral microsomes. Nunn and Ponnusamy [42] reported that liver and kidney homogenates, 
but not brain homogenates, formed methylamine and 2,3-diaminopropanoic acid when incubated   
with L-BMAA. In contrast, Kisby and colleagues [43] found that rodent brain tissue metabolized both 
L-BMAA and aminopyrine (standard substrate for cytochrome P450) to the genotoxin formaldehyde, 
enzymatic reactions that were inhibited by the aminopyrine N-demethylase inhibitors deprenyl, 
SKF525A and piperonyl butoxide (Figure 5).  
L-BMAA also interfered with brain RNA and protein synthesis when the amino acid was incubated 
with mouse cortical explants or administered intraperitoneally to adult rats (100 mg/kg) (Figure 6). In 
summary, while L-BMAA can act as a glutamate agonist, the amino acid is also taken up by brain 
tissue, forms a genotoxic metabolite, and regionally interferes with brain RNA and protein synthesis. 
These provocative findings suggest that further work on the non-excitotoxic properties of L-BMAA is 
merited, and it is premature to exclude the cycad amino acid as a participant in the etiology of western 
Pacific ALS-PDC.  Int. J. Environ. Res. Public Health 2011, 8         
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Figure 5. Metabolism of L-BMAA by the brain cytochrome P-450-dependent N-demethylase. (A) 
Disappearance of L-BMAA after incubation with rat cerebral microsomes 
1; (B) Metabolism of 
L-BMAA by crude microsomes derived from mouse cortical explants 
2;  (C) Effect of the   
N-demethylase inhibitor deprenyl on the metabolism of L-BMAA by rat cerebral microsomes 
3; 
(D) Effect of the cytochrome P450 inhibitors SKF525A and piperonyl butoxide on the 
metabolism of L-BMAA by rat cerebral microsomes and mitochondria 
4. Graphs derived from 
Kisby et al. [43] and unpublished data. 
 
 
1  Cerebral microsomes were prepared from adult Sprague-Dawley rats (n = 2) according to [44], diluted 
with buffer to a final concentration of 10 g protein/mL and incubated at 37
oC with 1.6 mM L-BMAA in 
the presence of 1.0 mM NADPH. At various time periods, an aliquot (100 L) was ultrafiltered (10 K 
MWCO) and the ultrafiltrate analyzed for L-BMAA content by HPLC [45]. L-BMAA disappeared with 
time, an indication that it was metabolized by cerebral microsomes;  
2  Explants (n = 15) were sonicated (2 × 10 s) on ice in 500 l of ice-cold PBS, the homogenate centrifuged 
(16,000 × g) and an aliquot of the supernatant (crude microsomal fraction) taken for protein determination. 
The aliquot was incubated with 1.6 mM aminopyrine or L-BMAA and N-demethylase activity determined 
[44]. Samples were run in triplicate, averaged and the results expressed as nmoles of formaldehyde/min/mg 
protein ± standard error;  
3  An aliquot of protein was incubated with 1.6 mM aminopryine or L-BMAA in the presence or absence of  
0.1  M or 0.5 M deprenyl, an aminopyrine N-demethylase inhibitor [46], and N-demethylase activity 
determined [44]. Deprenyl had a significant influence on the metabolism of both aminopyrine and   
L-BMAA and the effect of this inhibitor on L-BMAA metabolism was concentration-dependent;  
4  An aliquot of microsomal or mitochondrial protein was incubated with 1.6 mM aminopyrine or 1.6 mM  
L-BMAA in the presence or absence of either 100 M SKF525A or 500  piperonyl butoxide and  
N-demethylase activity determined [44]. Results are expressed as % N-demethylase activity relative to 
controls. The N-demethylase activity of control microsomes and mitochondria were comparable to that 
previously reported [44]. The N-demethylation of aminopyrine and L-BMAA was inhibited by piperonyl 
butoxide and SKF525A in both brain microsomes and mitochondria; an indication that L-BMAA is 
metabolized to formaldehyde by mixed function oxidases. Significantly different from microsomes incubated 
with aminopyrine or L-BMAA (
† p < 0.05; * p < 0.01; ** p < 0.001). Int. J. Environ. Res. Public Health 2011, 8         
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Figure 6. Effect of L-BMAA on rodent brain RNA and protein synthesis.   
(A) Effect of L-BMAA (24 h) on RNA and protein synthesis in mouse cortical explants 
1;  
(B) Effect of L-BMAA on RNA and protein synthesis in various brain regions of adult  
rats 
2. Graphs derived from unpublished data. 
 
1  Explants from the motor cortex of 2-day-old Swiss Albino mice were maintained for 2–3 weeks before 
treatment for 24 h with 1.6 mM L-BMAA, as previously described by Kisby et al. [40]. Immediately after 
L-BMAA treatment, the explants were incubated with a solution containing   
[5-
3H]-uridine (19.0 Ci) and L-[1-
14C]-leucine (0.95 Ci), the explants washed with buffer, the tissue 
homogenate fractionated and the supernatant (RNA) and pellets (protein) examined for radioactivity as 
previously described by Pickard et al. [47]. Values are expressed as CPM/mg protein;  
2  Adult male rats were administered a single intraperitoneal injection of vehicle (100 mM sodium 
bicarbonate, n = 8; Control) or L-BMAA (100 mg/kg, n = 8) daily for 14 days. Treated animals were 
injected intraperitoneally with a mixture containing [5-
3H]-uridine (1.7 mCi/kg) and  
L-[1-
14C]-leucine (84 Ci/kg); 30 min later, the brain was excised and dissected into various regions, 
homogenized and the tissue fractions examined for radioactivity as previously described [47]. Values are 
expressed as CPM/mg protein. Significantly different from control treated explants or brain tissue   
(* p < 0.05; ** p < 0.01; *** p < 0.001). MCTX = motor cortex. HIPP = hippocampus.   
STR = striatum. CB = cerebellum. 
2.2. Cycad Toxins: Azoxyglycosides and Methylazoxymethanol (MAM) 
While further study of L-BMAA and its genotoxic metabolite in relation to ALS-PDC is 
encouraged, the results of our recent toxicogenomic studies have focused attention on a possible and Int. J. Environ. Res. Public Health 2011, 8         
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perhaps more important etiologic role for MAM (Figure 7), the genotoxic metabolite of cycasin. 
Whereas cycads contain small concentrations of L-BMAA, cycasin—the glucoside of the potent DNA 
alkylating agent MAM—accounts for 4% w/w of Cycas seed [48]. Cycasin is thus delivered in much 
larger doses than L-BMAA when the raw seed is used as an oral tonic (Kii, Japan) or for wound repair 
(Guam, West Papua). Secondly, there is a striking correlation between the cycasin content of cycad 
flour and the historical age-adjusted incidence of both ALS and PD among both male and female 
villagers of Guam [49,50]. Third, MAM acetate is a developmental neurotoxicant that is used by the 
experimental neurobiologist as a reliable tool to disrupt regional brain development. Cycasin also 
induces cycadism, a neuromuscular disorder seen in large grazing animals (cows, goats) after ingestion 
of cycads [51]. Cycadism can be triggered by cycad plants containing various azoxyglycosides other 
than cycasin, all of which release MAM upon enzymatic hydrolysis [48] (Figure 7).  
Figure 7. Structure of the cycad genotoxins cycasin (methylazoxymethanol--D-glucoside), 
methylazoxymethanol (MAM) and the related compound azoxymethane (AOM). The 
azoxyglycoside cycasin is converted to MAM by plant and animal -glucosidases whereas 
azoxymethane is converted to MAM by mixed function oxidases (i.e., P450 Cyp2E1). 
 
However, experimental studies that have tested the effects of cycad and components thereof   
on laboratory species are difficult to interpret. An early study [52] reported the development of an 
ALS-like disorder (unilateral arm weakness) in one of three monkeys fed Chamorro-style cycad flour, 
but another cancer-focused study with a larger number of animals treated with cycasin or MAM 
neither reported the neurological status nor examined the nervous system   
microscopically [53,54]. Studies of adult rodents have focused on the carcinogenic potential of cycad 
and cycasin, although cerebellar pathology was reported in a study of rats fed L-BMAA [55]. A recent 
experimental study of rats fed cycad materials (cycasin content unknown) found neuropathological 
changes in the substantia nigra, striatum, locus coeruleus and cingulate cortex [56] which, as the 
authors note, supports the proposed role of cycad in western Pacific ALS-PDC, a proposal first made 
by Whiting and Kurland, later resurrected by Spencer and colleagues, and now once again the subject 
of intense biomedical interest. Shaw and his colleagues, the authors of the recent rodent study, propose Int. J. Environ. Res. Public Health 2011, 8         
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that cycad sitosterols—either as the free sterol or the glucoside—are likely etiological agents; this 
seems unlikely since these compounds are used to treat prostatic hypertrophy without reported 
neurological disease, and controlled toxicological studies have given these sterols a clean bill of   
health [57].  
3. Other Botanical Toxins, Toxicants and Neurodegenerative Disease 
Western Pacific ALS-PDC has also been linked to a clinically similar atypical parkinsonism with 
tauopathy that occurs on the island of Guadeloupe in the Caribbean [58]. It is unclear whether this is a 
progressive disease; the initial report described self-limiting and even reversible forms of high-incidence 
parkinsonism and ALS. Guadeloupe tauopathy is associated with the heavy use for food and beverage 
of the sour sop or corossol (Annona muricata). It is claimed that Annonaceae have been commonly 
consumed in foci of atypical parkinsonism, including Guam, Guadeloupe and New Caledonia (where 
Cycas spp. also occur but uses in the latter two are unexplored). Annonaceae certainly merit further 
study for links with neurodegenerative disease because they contain substances with probable 
neurotoxic potential [59]. These include alkaloids and annonacin, the most abundant acetogenin, a 
potent mitochondrial Complex 1 inhibitor. Inhibitors of Complex 1 (1-methyl-4-phenyl-1,2,3,4 
tetrahydro-pyridine, rotenone) or Complex 2 (3-nitropropionic acid) are linked with neurotoxicity, but 
generally precipitate self-limiting neurodegeneration in humans and laboratory animals.   
Cyanide-liberating cassava (Manihot esculenta), a plant with established neurotoxic potential, was also 
consumed on Guam, but not in Kii-Japan or West Papua. Dietary dependency on cassava in the 
absence of adequate protein intake can trigger a self-limiting neurodegenerative disease (cassavism) 
featured by spastic paraparesis which, like lathyrism, is quite distinct from western Pacific ALS-PDC 
[60]. Unlike the cycad, none of the above, notably cassava and sour sop, is common to all three foci of 
western Pacific ALS-PDC and neither induces a progressive motorsystem disease. 
There are other clues implicating cycad seed in the etiology of western Pacific ALS-PDC, a 
disorder that affects systems other than the nervous system. Peripheral malignancy is an obvious 
potential outcome based on the mutagenic properties of cycasin and the compound’s ability to induce 
tumors in primates and rodents [53,54,61]. Unfortunately, there are sparse data on cancer incidence in 
Guam [62], and no attempt has been made to correlate tumor incidence with neurodegenerative disease 
or neurodevelopmental disorders. However, the integument and skeleton do provide possible links 
with cycadism. Ruminants grazing on cycad leaves lose their horns and hooves in the manner of a 
molt, where dermal regeneration is active [51]. In parallel fashion, cycad seed materials have been 
experimentally demonstrated in rodents to speed skin repair, which is consistent both with their 
therapeutic use to treat dermal injuries in Guam and West Papau, and with the resistance to bed sores 
of bedridden ALS patients on Guam (and elsewhere). ALS skin loses its normal elasticity and, on 
microscopic examination, is found to contain thin collagen and elastin fibers that are consistent with 
regeneration. Chamorros historically have had a high prevalence of diaphyseal aclasis, which is visible 
as non-malignant bony protuberances near the growing ends of long bones in the upper extremities [1]. 
In sum, these observations raise the possibility that a component within cycad activates molecular 
processes associated with epidermal growth. An unpublished study showing unusual skull bone 
thickness among Chamorros with ALS or PD is consistent with this idea.  Int. J. Environ. Res. Public Health 2011, 8         
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4. Cycasin and Brain Development 
“Only small amounts of [cycad] are given to children because many become ill when they eat a 
dish made with cycad starch” [21]. 
Given that cycasin is an established developmental neurotoxin, it would be of interest to understand 
if there is a relationship between cycad exposure during perinatal development and western Pacific 
ALS-PDC. Borenstein and colleagues [63] showed that exposure to cycads during childhood or young 
adulthood, but not adulthood, is an important risk factor for GD and PDC. Evidence of exposure to a 
genotoxin early in development is suggested by the presence of ectopic, multinucleated, Purkinje-like 
cells in the cerebellum of Guam and Kii subjects who died of ALS-PDC in middle or late   
life [64]. Guam ALS-PDC neurons with tau inclusions also contain mitotic markers [65]; such changes 
result from disruption of neuronal development, as occurs in neonatal rodents treated with cycasin or  
MAM [66]. These findings are consistent with emerging evidence indicating that neurons in AD and 
other tauopathies exhibit binucleation, cell cycle disturbances, and aneuploidy [67-69]. Thus, the work 
on the etiology of western Pacific ALS-PDC and related tauopathies has raised some interesting 
questions. Is the developing brain more vulnerable to cycad genotoxins (cycasin, MAM, L-BMAA?) 
than the mature brain? Do the early changes induced by cycad genotoxins in the developing brain 
herald the onset of changes that culminate in neurodegenerative disease? Similar questions were raised 
almost a decade ago to explain how environmental factors might elicit progressive neurodegenerative 
disorders such as Parkinson’s disease (PD) and AD [70]. Answers to these questions are likely to 
provide further insight into the underlying mechanisms of GD, PDC and related tauopathies, since 
there is growing evidence that neurodegeneration and carcinogenesis share a number of cellular 
pathways [71,72]. 
We have explored the relationship between early life exposure to cycasin and western Pacific   
ALS-PDC by examining the response of the developing rodent brain to MAM, the active metabolite of 
cycasin. MAM alkylates brain tissue DNA to produce N7-methylguanine (N7-mG) and   
O
6-methylguanine (O
6-mG) DNA lesions [48] when administered to rodents either in utero [73,74] or 
after birth [75,76]. N7-mG and O
6-mG DNA lesions are repaired by the base-excision and direct 
reversal (i.e., O
6-methylguanine methyltransferase, MGMT) repair pathways, respectively [77]. These 
DNA lesions also accumulate and may persist in the brain of fetal rats or neonatal mice after a single 
injection of MAM or related alkylating agents [48,75,78] because the repair of these DNA lesions in 
the rodent brain varies across different regions (Figure 8) and is significantly less efficient than in 
other organs (e.g., liver) [79]. O
6-mG DNA lesions have greater persistence in rodent   
brains [48,75,78], and they are highly mutagenic at the level of transcription in human cells, leading to 
an altered protein load, especially in cells with significantly reduced MGMT [80]. Since the fetal and 
young adult human brain also have a low or absent capacity to repair alkylation-induced DNA   
damage [81,82], the immature rodent is a good animal model to examine the response of the human 
brain to the cycad genotoxin MAM.  
Global gene expression profiling [75] and proteomic studies [83] of the brain of neonatal mice 
administered a single injection of MAM (21.5 mg/kg) showed that the cycad genotoxin produces an 
early and persistent increase in DNA damage, and disrupts the expression of genes and proteins that 
regulate the neuronal cytoskeleton, protein degradation and mitochondrial metabolism. Global gene Int. J. Environ. Res. Public Health 2011, 8         
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expression profiling of young post-mitotic cerebellar neurons and astrocytes treated in vitro with 
MAM demonstrated that immature neurons are more vulnerable than astrocytes, and this vulnerability 
to MAM is associated with the accumulation of DNA lesions and distinct alterations in gene 
expression [84]. The preferential targeting of genes involved in such diverse functions as cell 
signaling, transcriptional regulation, differentiation, and the stress and immune response, suggests that 
MAM targets distinct neuronal networks in the developing brain. This is supported by the insensitivity 
of adult neurons to MAM [66]. Since these cellular pathways are also disturbed in neurodegenerative 
disease, and the undeveloped human brain is particularly inefficient at repairing alkyl DNA lesions 
(i.e., O
6-mG) [81,82], MAM may have targeted one or more of these pathways by a DNA damage-
mediated mechanism. While O
6-mG DNA lesions are cytotoxic and mutagenic (in cycling cells), their 
persistence for long periods in neurons [78] could disrupt brain function and provide the critical 
substrate for enhanced predisposition to late-life neurodegenerative disorders. Therefore, the DNA 
damage produced by MAM in the undeveloped human brain may constitute an important, but 
relatively unacknowledged cause of the synuclein and tau pathology in western Pacific ALS-PDC and 
other tauopathies [63,85].  
Figure 8. O
6-Methylguanine methyltransferase (MGMT) activity in various brain regions 
of neonatal mice. Protein extracts (100 g) from postnatal (6–8) brain tissue of wild type 
(C57BL6) mice (n = 3) were incubated with [
3H]-methyl-DNA and the amount of [
3H]  
O
6-methylguanine determined by HPLC with liquid scintillation counting. Values are the 
mean ± standard error. CX = cortex, HP = hippocampus, TH = thalamus, MB = midbrain, 
CB = cerebellum, BS = brainstem (graph of unpublished data kindly provided by S.L. 
Gerson, Case Western Reserve University, Cleveland, OH, USA). 
 
While DNA damage is a characteristic feature of synucleinopathies and   
tauopathies [86-89], how the DNA damage produced by cycad genotoxins might contribute to western 
Pacific ALS-PDC is not understood. To address this central issue, we compared the response of the 
neonatal brain of DNA repair-proficient (wild type, C57BL6/J), –deficient (Mgmt
−/−)  
and – overexpressing (Mgmt
Tg+) mice to MAM or related genotoxins including the methylating agent 
dimethyl sulfate (DMS), the monofunctional or bifunctional chloroethylating agents chloroethylamine 
(CEA) and nitrogen mustard (HN2) [75,76]. MAM methylates DNA to produce N7-mG and O
6-mG 
DNA lesions, whereas HN2 rapidly and irreversibly alkylates guanine (G) and adenine (A)   
(e.g., N7-alkylG and 3-alkylA, respectively) of DNA to produce monoadducts, intrastrand cross-links Int. J. Environ. Res. Public Health 2011, 8         
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and interstrand cross-links. Dimethyl sulfate is a methylating agent that produces primarily N7-mG 
and 3-methyladenine DNA lesions, while CEA, the monofunctional analogue of nitrogen mustard, 
produces predominantly N7-alkylG DNA lesions, but not cross-links. The primary objective of using 
MAM and related alkylating agents was to determine if these genotoxins induce their long-term effect 
on neurons in the developing brain through the generation of specific DNA lesions. By comparing the 
response of the neonatal brain to MAM and related alkylating agents among these DNA repair 
genotypes, we would be able to determine if the DNA lesions produced by the cycad genotoxin are 
linked to neuropathological and associated neurobehavioral changes. Neurodevelopment and motor 
function were more severely affected by MAM in Mgmt
−/−  mice than after treatment with other 
alkylating agents (i.e., dimethylsulfate, nitrogen mustard), and these effects were less pronounced in 
similarly treated wild-type mice [76]. The reduced number of Mgmt
Tg+ neurons undergoing apoptosis 
and the preservation of cerebellar morphology and motor function in MAM-treated Mgmt
Tg+ mice is 
additional evidence that MGMT plays an important role in protecting the undeveloped brain from 
cycad genotoxin-induced injury. These findings indicate that one pathway by which the cycad 
genotoxin MAM induces its neurotoxic effects is through the production of O
6-mG DNA lesions.  
5. Cycasin and the Young Adult Brain 
Estimates suggest that exposure of young adults to the picking, processing and eating of cycad food 
products (fadang) incurred the highest attributable risk for mild cognitive impairment (MCI), GD and 
PDC among Guam Chamorros [63,85]. In comparison, there was no association between the picking, 
processing or eating of fadang among adults and risk for MCI, GD, or PDC. Thus, the incompletely 
developed human brain appears to be especially vulnerable to cycad genotoxins. We explored this 
hypothesis further by examining the response of the young adult murine brain to the cycad genotoxin 
MAM. As in the neonatal studies [75,76], both DNA repair-proficient and Mgmt knock-out (Mgmt
−/−) 
mice were used to determine if DNA damage also plays an important role in the response of the young 
adult brain to cycad genotoxins. 
Global gene expression profiling was used to compare the extent of MAM-induced DNA   
damage (i.e., O
6-mG) with the response of the young adult brain of both DNA repair-proficient mice 
(C57BL6/J) and DNA repair-deficient (Mgmt
−/−) animals [90]. The brains of young adult   
Mgmt
−/− mice treated with a single systemic dose of MAM showed significantly higher levels of O
6-
mG than the brains of comparably treated C57BL6/J wild-type mice. The DNA damage in the brain of 
MAM-treated young adult Mgmt
−/− mice remained elevated (up to 7 days post-treatment), an 
indication that O
6-mG lesions are persistent and MGMT is essential for removing the DNA damage 
(whether produced by MAM or related alkylating agents) [78,91,92]. The O
6-mG levels were linked to 
changes in the expression of genes in several cell-signaling pathways (i.e., TP53, NF-kB, MAPK) 
associated with cancer, neurological disease, neurodevelopmental and skin disorders. These data are 
consistent with the established developmental neurotoxic and carcinogenic properties of MAM in 
rodents [93-96]. The prominent modulation of ‘cancer genes’ in the “tumor-insensitive” brains of 
MAM-treated young adult animals suggests that perturbations of these genes in the undeveloped brain 
have consequences other than cancer. They also support the hypothesis that early-life exposure to 
MAM-glucoside (cycasin) has an etiological association with western Pacific ALS-PDC.  Int. J. Environ. Res. Public Health 2011, 8         
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The experience of Chamorro migrants from Guam to the continental United States shows that   
ALS-PDC may surface clinically years or decades after they leave the Guam   
environment [97]. Similarly, occasional non-Caucasian migrants to Guam have lived in the Chamorro 
culture for years or decades before developing clinical signs of ALS-PDC [98]. Comparable “latent 
periods” have been noted in individuals who developed ALS after treatment with raw cycad seed either 
by the oral route (Kii-Japan) or subcutaneously (West Papua) [25,26]. Neuropathological signs of sub-
clinical tauopathy have been reported in Chamorros who died without evidence of neurological   
disease [99]. Taken, in concert, therefore, the agent responsible for the induction of western Pacific 
ALS-PDC triggers a pathological process that advances long after exposure has terminated. We have 
therefore undertaken preliminary studies to determine if MAM induces latent transcriptional changes 
in the brains of Mgmt
−/−  vs. wild-type mice. Brain transcriptional changes 6 months after single 
systemic treatment with MAM (MAMlate) were comparable to those seen at 7 days post-MAM 
treatment, and there was elevation of mitogen-activated protein kinases and increased caspase-3 
activity, both of which are involved in tau aggregation and neurofibrillary tangle formation typical of 
ALS-PDC and AD [100]. Additionally, the MAMlate transcriptional profile was dominated by the 
presence of 28 genes involved in olfactory transduction, which suggests the presence of a   
MAM-induced change in olfaction status. While caution is merited when comparing rodent and human 
data, olfactory dysfunction is among the first signs of neurodegenerative disease [101]. Marked 
olfactory deficits, first reported in Guam PDC, are also similarly present in Chamorro patients with 
ALS, pure parkinsonism, and pure dementia, and in some controls with possible sub-clinical   
ALS-PDC [102]. Olfactory deficits are also among the first signs of AD and idiopathic   
PD [103,104]. The inability to distinguish the nature of olfactory dysfunction among Guam PDC,   
AD [105] and ALS patients [102], suggests a common neurologic substrate and underlines the close 
relationship between ALS-PDC and the more familiar neurodegenerative disorders seen in the West. 
These findings suggest that environmental genotoxins, specifically MAM, target common pathways 
involved in neurodegeneration and cancer, the outcome depending on whether the cell can divide 
(cancer) or not (neurodegeneration) [90]. Both phenotypes, it should be noted, represent diseases that 
surface clinically long after exposure terminates. Others have proposed links between 
neurodegeneration/cancer and cell cycle regulation, DNA repair, response to oxidative   
stress [72,106], aberrant wingless and proto-oncogene Int-1 (Wnt) signaling [107], glycogen synthase 
kinase 3-beta  (GSK3) regulation [108], modulation of tumor protein 53 (TP53 or P53)   
expression [109], and perturbations of tau in AD and prostate cancer [110]. Chronic tissue 
inflammation is another characteristic feature of both cancer, AD [111] and western Pacific ALS-PDC 
brain. Further investigation of the cell signaling pathways that are activated by MAM in the immature 
brain might help us understand how the disruption of ‘cancer genes’ could contribute to 
neurodegenerative disease or neurodevelopmental disorders. 
These provocative findings suggest that the cycad genotoxins cycasin and MAM induce their 
neurotoxic effects through molecular mechanisms similar to those reported in the azoxymethane 
(AOM) mouse model of colorectal adenocarcinoma in which MAM (the cytochrome P450 2E1 
mediated metabolite of AOM; see Figure 7) is the sole triggering agent [96,112]. In the AOM mouse 
model, MAM-induced O
6-mG DNA lesions lead to mutations in K-ras (i.e., transversion from G:C to 
A:T at codon 12) and -catenin (i.e., transversion from G:C to A:T at codons 33, 34, 37, and 41; serine 
and threonine sites phosphorylated by GSK-3) [113,114], resulting in the downstream activation of Int. J. Environ. Res. Public Health 2011, 8         
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several cell signaling pathways, including phosphoinositide 3-kinase/Akt (PI3K/Akt), MAPK and   
Wnt [112]. Such events may explain how MAM modulates the expression of genes with pivotal roles 
in cell signaling in the brain of young adult mice (Figure 9).  
Figure 9. Proposed relationship between MAM-induced colon cancer and brain 
disease/disorders. Genotoxins, such as methylazoxymethanol (MAM), that induce   
O
6-methyldeoxyguanine lesions (O
6-mdG DNA damage), disturb cell signaling pathways, 
including transforming growth factor- (TGF-), wingless and proto-oncogene Int-1 
(Wnt), and mitogen-activated protein kinase (MAPK). In general, the literature supports  
up-regulation (green) and down-regulation (pink) in association with the two distinct 
phenotypes. (Modified from Chen and Huang [112]). Thus, MAM may have opposing 
effects that depend on the mitotic state of the cell: whereas the agent may induce 
mutagenesis and proliferation (tumorgenesis) in cycling cells, in non-cycling cells   
(i.e., neurons) the outcome is cellular degeneration. 
 
Since neurons in the young adult brain are post-mitotic, MAM-induced O
6-mG DNA lesions likely 
perturb these pathways by disrupting the binding of transcription factors [115-119] or by activating 
transcriptional mutagenesis [80]. This is supported by recent studies showing that the binding of the 
p50 subunit of the NFkB transcription factor, a cell-signaling pathway that is perturbed by MAM in the 
rodent brain [90], is altered by a single O
6-mG or 8-oxoG DNA lesion (Figure 10).  Int. J. Environ. Res. Public Health 2011, 8         
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Figure 10. Autoradiograms showing the gel shift induced by binding of the p50 subunit of 
NF-kB to its DNA recognition sequence containing a DNA lesion. (A) Recognition 
sequence for the p50 subunit of NF-kB. Four oligonucleotides, each containing a guanine 
(G) or either an O
6-mG (B) or 8-oxoG (C) located in the consensus sequence of the p50 
subunit, were incubated with different concentrations of purified p50, electrophoresed and 
the autoradiograms examined for bands by chemiluminescence. The concentration 
dependence of the DNA-p50 complex was demonstrated by the addition of 0, 4, 8, or 16 ng 
of purified p50 in the reaction mixture. This suggests that binding of the transcription 
factor (NF-kB) to its cognate DNA recognition sequence is altered both by the nature and 
the specific location of the DNA lesion (images derived from unpublished data). 
 
The location as well as the type of DNA damage had a pronounced influence on binding indicating 
that a persistent DNA lesion could have a significant effect on gene expression. However, if these 
DNA lesions occur in the transcribed strand of an active gene, they could miscode leading to mutant 
transcripts and proteins, a process known as transcriptional mutagenesis [120,121]. Recent studies by 
Burns and colleagues [80] provide strong support for this hypothesis by showing that a single O
6-mG 
DNA lesion located within the coding sequence of a reporter gene produced both altered RNA and 
protein levels. An active gene that contains O
6-mG in a position sensitive to T or C transition could 
produce as much as 66% altered transcripts. If these lesions persist in the young adult brain, they 
would have a detrimental influence on brain function. Int. J. Environ. Res. Public Health 2011, 8         
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6. Relevance to Neurodegenerative Disorders 
While the proposed link between human exposure to cycad genotoxins (cycasin, MAM, L-BMAA?) 
and western Pacific ALS-PDC is controversial, equally provocative suggestions have raised the 
possibility that related chemicals in the North American environment may be linked to sporadic PD 
and AD. Epidemiological studies published a couple of years ago by de La Monte   
and colleagues [122] noted strong parallels between the age-adjusted increases in the death rate from 
AD, PD and diabetes mellitus, and progressive increases in human exposure to nitrates, nitrites and 
nitrosamines through processed and preserved foods as well as fertilizers. By contrast, other diseases, 
including HIV-AIDS, cerebrovascular disease, and leukemia, did not exhibit those trends. De la Monte 
and colleagues propose that the increase in exposure to these environmental chemicals plays a critical 
role in the cause, development and the effects of these diseases through an insulin-resistant 
mechanism. Just as the cancer research community decades ago called for a reduction in exposure to 
nitrite preservatives in food [123], the question of a relationship between exposure to such compounds 
and neurodegenerative disease is now an issue. The basis for focusing on nitrite preservatives is their 
transformation in the gut to genotoxic nitrosamines. 
N-Nitrosamines are potent carcinogens that occur widely in the environment, and they are also 
formed endogenously in the stomach following the interaction of ingested nitrate or nitrite with 
secondary amines (e.g., proteins) [124]. Human exposure to nitrosamines or their precursors, nitrates 
and nitrites, can also occur from exogenous sources, such as diet [125], drinking   
water [126], occupation (e.g., rubber industry) [127], or environmental exposures (Table 1). 
Nitrosamines, like MAM, are potent alkylating agents that methylate DNA to produce N7-mG and  
O
6-mG DNA lesions [128]. The antineoplastic agent streptozotocin (STZ), a monofunctional 
nitrosourea derivative isolated from Streptomyces achromogenes, is also a potent alkylating and highly 
genotoxic agent known to directly methylate DNA. Since antineoplastic agents impair   
cognition [129] and the effects are persistent [130], these agents might also induce both structural and 
functional changes in the immature brain through a DNA damage-mediated mechanism. 
Table 1. Common Sources of N-Nitrosamines.
Source  N-Nitrosamine 
† Concentration 
Food/Beverages    
Bacon  DMN, DEN, NPYR   1–40 ppb 
Salami DMN  10–80  ppb   
Luncheon meat  DMN, DEN  1–4 ppb 
Hamburger DMN  15–25  ppb 
Chinese marine salted fish  DMN DEN  0.05–21 ppm 
Smoked salmon  DMN  0–26 ppb 
Cheese DMN  1–4  ppb 
Wheat flour  DEN  0–10 ppb 
Beer DMA   Int. J. Environ. Res. Public Health 2011, 8         
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Table 1. Cont. 
Source  N-Nitrosamine 
† Concentration 
Commercial Products     
Latex gloves  DMN  37–329 ppb 
  DEN  < 10 µg/kg 
Cigarettes  DMN, DEN, NPYR  0–180 ng/cig. 
Pesticide Formulations  DMN  300 ppb–640 ppm 
Rubber nipples  DMN, DEN  < 100–200 µg/kg 
Rubber toys  DMN  < 25 µg/kg 
Rubber balloons  DMN  < 150 µg/kg 
  DEN  > 30 µg/kg 
Industrial Exposure    
Leather Tanneries  DMN  0.1–47 µg/m
3 
Foundries, USA  DMN  0.062–2.4 µg/m
3 
Rubber, curing, salt bath  DMN, DEN   
Rubber, curing, injection molding  DMN   
    
* Source: Thomson et al. [131]; † Abbreviations: DMN (NDMA): N-nitrosodimethylamine; 
DEN (NDEA): N-nitrosodiethyl- amine; NPYR: N-nitrosopyrrolidine; DMA:   
N-nitrosodimethylamine. 
MAM reproducibly induces brain maldevelopment by a DNA damage mechanism [76], but how 
this cycad toxin might induce chronic neurodegenerative disease is not understood. One possibility is 
that MAM perturbs the brain insulin-signaling pathway like the related genotoxins STZ [132] and 
nitrosamines [133]. STZ, a glucosamine of N-methylnitrososurea, induces a rodent model of dementia 
that is characterized by progressive deterioration of memory, energy metabolism [134], and tau 
pathology [135,136]. The tau pathology in the STZ rodent model of dementia is preceded by early 
changes in the phosphatidylinositol-3-kinase (i.e., PI3K, phospho-Akt, GSK-3) insulin/IGF-signaling 
pathway [137]. Nitrosamines also perturb the brain insulin/IGF-signaling pathway (i.e., insulin, IGF, 
IGF receptors, GSK 3) when administered to neonatal (postnatal day 3) rats [133,138]. Like STZ, the 
effect of nitrosamine on the brain insulin/IGF-signaling pathway precedes the tau pathology   
(i.e., tau, phospho-tau) and cognitive impairment. MAM induces similar changes in the brain of mice 
that overexpress normal human tau (i.e., htau) (Figure 11) suggesting this environmental genotoxin is 
also capable of inducing tau pathology by a mechanism similar to that activated by streptozotocin and 
nitrosamines. Since IGF and GSK-3 are also perturbed in the brain of Guam and Japanese ALS/PDC 
patients [139], and insulin resistance is an established risk factor for dementia [140,141], the cycad 
genotoxins might induce tau pathology in GD and PDC by inducing brain insulin resistance. Int. J. Environ. Res. Public Health 2011, 8         
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Figure 11. MAM induces Tau phosphorylation in the brain of htau mice. Neonatal (PND3) 
htau mice (mouse mutant that overexpresses normal human Tau) were given a single 
subcutaneous injection of saline or MAM (22 mg/kg). The hippocampus of the offspring 
was examined at post-natal day 90 for the phosphorylation of Tau at serine 199 (pS199). 
Note the heavy accumulation of pS199 within the axons (arrowheads) of CA1 and CA3 
pyramidal neurons after MAM treatment. Tissue slides were prepared for 
immunohistochemistry according to Kisby et al. [83]. Magnification, x40 [images kindly 
provided by R. Woltjer (OHSU) and derived from unpublished data].  
 
7. Summary and Putative Molecular Mechanisms 
Western Pacific ALS-PDC, a neurodegenerative disease prototypical for human tauopathies such as 
AD, has been described in three geographic isolates among genetically distinct people. The common 
features of the disease in Guam, Kii and West Papua are the combination of high-incidence clinical 
ALS, PD and overlapping forms in single populations; decreasing overall prevalence of ALS-PDC 
with societal development, with ALS declining before PD; and a common neuropathology (not studied 
in West Papua). The cause of ALS-PDC is unknown but a common, non-infectious environmental 
factor with declining access to the three high-risk groups is highly probable. The leading candidate for 
the culpable agent is one or more neurotoxins in cycads, ancient plants long established as causal of 
neuromuscular disease in grazing animals. Raw cycad seed has been used for medicinal purposes in all 
three ALS-PDC foci, and incompletely detoxified cycad seed flour has been an important food item in 
Guam, as have cycad-eating flying foxes: these traditional practices have declined with acculturation 
to modern life. Cycad chemicals include (among many others, most of which have yet to be identified) 
the uncommon amino acid L-BMAA, a compound with excitotoxic properties mediated by glutamate 
receptors and the azoxyglucoside cycasin, which forms the potent developmental neurotoxin MAM. 
Both MAM and L-BMAA are taken up by brain tissue, where they are metabolized to compounds with 
genotoxic properties including the carcinogen formaldehyde, which has twice been linked with ALS in 
the US and UK [142,143]. Primates fed large doses of L-BMAA develop a motorsystem disease 
featured by chronic degenerative changes of cortical and spinal motor neurons, neurofibrillary tangles, 
and extrapyramidal dysfunction. MAM induces DNA lesions that markedly disrupt rodent brain Int. J. Environ. Res. Public Health 2011, 8         
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development and, in the young adult brain, activate intracellular signaling pathways linked with human 
neurological disease (tauopathies) and cancer. Neurodegeneration and cancer may be associated with 
similar pathways in cycling cells and non-cycling cells (neurons), respectively, the ability of the cell to 
divide, rather than an intrinsic toxic property of the culpable agent, determining phenotypic outcome. 
Labeling MAM and comparably acting chemicals as “carcinogens” or “neurotoxins” is therefore 
misleading. MAM-like alkylating agents (nitrosamines, hydrazine, streptozotocin), which are known 
for their carcinogenic potential, should be examined for potential long-latency neurotoxicity. 
If one or more cycad genotoxins play a role in the etiology of western Pacific ALS-PDC, we must 
explain both the differential clinical presentation (ALS, PD, GD) and the long latent period (years, 
decades) that intervenes between exposure and the appearance of clinical disease. Since ALS relative 
to PD usually occurs in younger patients, the time to onset of the motor neuron disease ALS is 
relatively short. This might result from early-life exposure to cycad materials or heavy exposure(s) to 
the culpable toxin, either or both precipitating clinical disease at younger ages. Since early-life 
exposure to cycads has been linked to Guam PD and GD, disorders that have a mean age of   
onset substantially higher than that of Guam ALS, this suggests that dosage is a critical factor in 
determining clinical outcome. Viewed from this perspective, therefore, large exposures may trigger 
fatal motor neuron disease (ALS and sub-clinical parkinsonism) in the relatively young (> 20 years of 
age), whereas lower exposures affect motor neurons to a lesser degree and thereby allow the subject to 
survive to an older age whereupon they develop PD or, later in life, Alzheimer-like Guam dementia.  
Another crucial question is the biological mechanism by which a cycad genotoxin can act as a 
“slow (neuro)toxin”, that is an agent that (like a carcinogen) triggers a neurodegenerative disease 
process that is initially covert but which, over a sufficient period of time, surfaces in clinical disease 
and progresses to a fatal outcome. Among the various possibilities, four pathogenic mechanisms may 
be considered: all postulate a persistent change in nerve cells, either as a result of unrepaired DNA 
damage or the presence of a mutant protein.  
One possibility postulates that normal synaptic activity, perhaps involving glutamate metabotropic 
receptors, would continuously drive DNA-damaged neurons to activate signal pathways involved in 
tau regulation, resulting in abnormal tau production, tau-rich neurofibrillary tangles and, ultimately, 
neuronal degeneration. Neurofibrillary brain pathology would be evident in sub-clinical forms of the 
disease but, as neuronal degeneration advanced relentlessly, the disease would eventually manifest 
clinically. With the Hugon laboratory, we tested the biological principle underlying this hypothesis 
using primary cultures of rat cortical neurons that responded to a short (“synaptic-like”) pulse of 
exogenous glutamate with a measurable increase in tau transcription. A comparable pulse of   
DNA-damaging MAM also increased tau mRNA, but when the application of MAM preceded that of 
glutamate, the resulting increase in tau transcription was greater than the sum of the two in   
isolation [144,145]. 
A second possibility is a mechanism known as transcriptional mutagenesis, which involves a 
persistent lesion in the coding region of a gene. While the mutagenic consequences of exposure to 
DNA-damaging agents like MAM can trigger cell proliferation in cycling cells (such as gut cells) 
leading to tumor formation, the consequences for transcription in non-cycling cells (such as neurons) 
are unknown, but perhaps include degeneration. Studies performed by Bregeon   
and colleagues [120] examined transcriptional activity on a DNA template containing a DNA lesion Int. J. Environ. Res. Public Health 2011, 8         
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(8-oxoguanine) placed at defined positions along the transcribed strand of a reporter gene. Luciferase 
expression was efficient, but error-prone transcriptional by-pass of 8-oxoguanine occurred in vivo, and 
this lesion was not repaired by the transcription-coupled repair machinery of mammalian cells. 
“Analysis of luciferase expression from 8OG:C-containing constructs showed that the generated 
aberrant mRNAs led to the production of mutant proteins with the potential to induce a long-term 
phenotypical change. These findings reveal that erroneous transcription over DNA lesions may induce 
phenotypical changes with the potential to alter the fate of non-replicating cells.” [120]. 
The third possibility is another form of transcriptional disruption associated with persistent lesions 
in the promoter region of a gene leading to erroneous expression of the associated protein. Bonfanti 
and colleagues [115] showed that O
6-mG, one of the DNA lesions produced by MAM, inhibited the 
binding of transcription factors to their cognate DNA sequences in a position-dependent manner. The 
O
6-mG lesion blocked DNA binding of NF-kB, Sp1 and SRF. We confirmed that binding of NF-kB to 
its cognate sequence can be disrupted in a position-dependent manner by the presence of O
6-mG in 
DNA (see Figure 10). The importance of these observations is that DNA lesions within the   
promoter (vs. the coding) regions of genes may produce persistent up- or down-regulation of genes. 
This may explain why NF-kB was a prominent hub in the brains of MAMearly and MAMlate animals. 
A fourth possibility that involves L-BMAA specifically is the substitution of this plant amino   
acid for alanine in protein synthesis, another route by which mutant proteins could be produced. 
Protein-bound L-BMAA has been reported in cycad flour and in brain tissue from Chamorro subjects 
with ALS-PDC [38,146]. Mutant neuroproteins are established causes of progressive human   
neurodegenerative diseases, such as kuru and other fatal disorders involving mutations (misfolded) 
neuronal prion proteins [147]. Kuru is a subacute neurodegenerative disease with tau-containing 
plaques; there is heavy involvement of the cerebellum as well as the caudate, putamen, and much of 
the cerebral cortex [148]. While the infectious property of the mutant prion protein has been the 
subject of great public health interest, there is no research on the gene-based mutational event that 
presumably triggered production of the first mutant prion protein. In this regard, it is noteworthy that 
the kuru-affected South Fore people of Papua New Guinea were exposed to cycad mutagens through 
the practice of chewing the fleshy cycad seed cover and spitting the contents into the food of kuru 
victims. Indeed, in the West Papua focus of ALS-PDC, where the ovule is only used as topical 
medicine for large open wounds, cycad seed is named “kurru”, meaning, simply, “seed of the tree” [9]. 
Is there an undiscovered link between kuru and the developmental neurotoxicity of MAM, which 
produces prominent cerebellar or cortical pathology depending on the timing of application?  
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